Fig. 1
From: fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study
Study design. Epoch 1 (fSCIG 10% ramp-up): ≤ 6 weeks. Epoch 2 (fSCIG 10% treatment): 1–3 years. Epoch 3 (safety follow-up): up to 1 year. Ab, antibody; AE, adverse event; fSCIG, hyaluronidase-facilitated subcutaneous immunoglobulin; IVIG, intravenous immunoglobulin; rHuPH20, recombinant human hyaluronidase; SAE, serious adverse event; SCIG, subcutaneous immunoglobulin